Reevaluation of prognostic significance of symptoms in Hodgkin's disease. 1985

P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari

The prognostic value--at diagnosis--of fever, sweating and weight loss, which enter the Ann Arbor B category, and of pruritus, whose influence on survival is still debated, were systematically reevaluated in 635 patients with Hodgkin's disease, observed between 1972 and 1982. By means of multivariate analysis an intrinsic, more negative prognostic value was demonstrated for each of the following symptoms: fever over 38 degrees C, weight loss more than 10% of body weight in the 6 months before admission, and severe pruritus, which is defined as being generalized, causing multiple excoriations and resisting local and systemic antipruritics. Patients with the mild counterparts of these symptoms, as well as sweats, were found to have a survival rate quite comparable with that of fully asymptomatic patients. A rearrangement of the Ann Arbor B constitutional symptoms which would replace sweats with severe pruritus might be more correct and more suitable for better selecting the patients who require more aggressive therapy.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011537 Pruritus An intense itching sensation that produces the urge to rub or scratch the skin to obtain relief. Itching,Pruritis
D001835 Body Weight The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms. Body Weights,Weight, Body,Weights, Body
D005334 Fever An abnormal elevation of body temperature, usually as a result of a pathologic process. Pyrexia,Fevers,Pyrexias
D006689 Hodgkin Disease A malignant disease characterized by progressive enlargement of the lymph nodes, spleen, and general lymphoid tissue. In the classical variant, giant usually multinucleate Hodgkin's and REED-STERNBERG CELLS are present; in the nodular lymphocyte predominant variant, lymphocytic and histiocytic cells are seen. Granuloma, Hodgkin,Granuloma, Malignant,Hodgkin Lymphoma,Lymphogranuloma, Malignant,Granuloma, Hodgkin's,Granuloma, Hodgkins,Hodgkin Lymphoma, Adult,Hodgkin's Disease,Hodgkin's Lymphoma,Hodgkins Disease,Lymphocyte Depletion Hodgkin's Lymphoma,Lymphocyte-Rich Classical Hodgkin's Lymphoma,Mixed Cellularity Hodgkin's Lymphoma,Nodular Lymphocyte-Predominant Hodgkin's Lymphoma,Nodular Sclerosing Hodgkin's Lymphoma,Adult Hodgkin Lymphoma,Disease, Hodgkin,Disease, Hodgkin's,Disease, Hodgkins,Hodgkin Granuloma,Hodgkin's Granuloma,Hodgkins Granuloma,Hodgkins Lymphoma,Lymphocyte Rich Classical Hodgkin's Lymphoma,Lymphogranulomas, Malignant,Lymphoma, Hodgkin,Lymphoma, Hodgkin's,Malignant Granuloma,Malignant Granulomas,Malignant Lymphogranuloma,Malignant Lymphogranulomas,Nodular Lymphocyte Predominant Hodgkin's Lymphoma
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000971 Antineoplastic Combined Chemotherapy Protocols The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form. Anticancer Drug Combinations,Antineoplastic Agents, Combined,Antineoplastic Chemotherapy Protocols,Antineoplastic Drug Combinations,Cancer Chemotherapy Protocols,Chemotherapy Protocols, Antineoplastic,Drug Combinations, Antineoplastic,Antineoplastic Combined Chemotherapy Regimens,Combined Antineoplastic Agents,Agent, Combined Antineoplastic,Agents, Combined Antineoplastic,Anticancer Drug Combination,Antineoplastic Agent, Combined,Antineoplastic Chemotherapy Protocol,Antineoplastic Drug Combination,Cancer Chemotherapy Protocol,Chemotherapy Protocol, Antineoplastic,Chemotherapy Protocol, Cancer,Chemotherapy Protocols, Cancer,Combinations, Antineoplastic Drug,Combined Antineoplastic Agent,Drug Combination, Anticancer,Drug Combination, Antineoplastic,Drug Combinations, Anticancer,Protocol, Antineoplastic Chemotherapy,Protocol, Cancer Chemotherapy,Protocols, Antineoplastic Chemotherapy,Protocols, Cancer Chemotherapy

Related Publications

P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
October 1995, Indian journal of pathology & microbiology,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
March 1965, The American journal of roentgenology, radium therapy, and nuclear medicine,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
January 1985, Cancer,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
January 2004, Anticancer research,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
April 1982, Cancer treatment reports,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
October 1983, Scandinavian journal of haematology,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
January 1984, Cancer,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
November 1984, European journal of cancer & clinical oncology,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
January 1979, Srpski arhiv za celokupno lekarstvo,
P G Gobbi, and C Cavalli, and A Gendarini, and A Crema, and G Ricevuti, and M Federico, and U Di Prisco, and E Ascari
January 1994, European journal of cancer (Oxford, England : 1990),
Copied contents to your clipboard!